# First-in-human Study of CA102N Monotherapy and CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors

> **NCT03616574** · PHASE1 · COMPLETED · sponsor: **Holy Stone Healthcare Co., Ltd** · enrollment: 37 (actual)

## Conditions studied

- Advanced or Metastatic Solid Tumors
- Advanced or Metastatic Colorectal Cancer (mCRC)

## Interventions

- **DRUG:** CA102N
- **DRUG:** LONSURF

## Key facts

- **NCT ID:** NCT03616574
- **Lead sponsor:** Holy Stone Healthcare Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-09
- **Primary completion:** 2022-02-08
- **Final completion:** 2022-03-01
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2022-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03616574

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03616574, "First-in-human Study of CA102N Monotherapy and CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03616574. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*